{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:13:45Z","timestamp":1771078425777,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":5283,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1093\/annonc\/mdi217","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T00:13:42Z","timestamp":1114474422000},"page":"1169-1176","source":"Crossref","is-referenced-by-count":60,"title":["In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas"],"prefix":"10.1016","volume":"16","author":[{"given":"K.","family":"Lacrima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Taborelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gianella-Borradori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"MacCallum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi217_bb0010","first-page":"3909","volume":"89","author":"Blood","year":"1997","journal-title":"Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma"},{"key":"10.1093\/annonc\/mdi217_bb0015","series-title":"Malignant Lymphoma","first-page":"27","article-title":"Mantle cell lymphoma","author":"Weisenburger","year":"2000"},{"key":"10.1093\/annonc\/mdi217_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","article-title":"Molecular basis of mantle cell lymphoma","volume":"124","author":"Bertoni","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi217_bb0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdi217_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3816\/CLM.2002.n.014","article-title":"Mantle cell lymphoma: new treatments targeted to the biology","volume":"3","author":"Bertoni","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdi217_bb0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine a potent and selective inhibitor of the cyclin-dependent kinases cdc2 cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1093\/annonc\/mdi217_bb0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdi217_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1517\/13543784.12.6.955","article-title":"CDK inhibitors in clinical development for the treatment of cancer","volume":"12","author":"Fischer","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1093\/annonc\/mdi217_bb0050","first-page":"210","article-title":"A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors","volume":"22","author":"Pierga","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdi217_bb0055","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood.V72.6.2026.2026","article-title":"Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14) (q13;q32)]","volume":"72","author":"Saltman","year":"1988","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi217_bb0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/gcc.2870080204","article-title":"Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies","volume":"8","author":"Raynaud","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1093\/annonc\/mdi217_bb0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1046\/j.1365-2141.1998.00911.x","article-title":"Establishment and characterization of a mantle cell lymphoma cell line","volume":"102","author":"Jeon","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi217_bb0070","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2400555","article-title":"Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519)","volume":"11","author":"Jadayel","year":"1997","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdi217_bb0075","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1021\/bi963101b","article-title":"Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26","volume":"36","author":"Catapano","year":"1997","journal-title":"Biochemistry"},{"key":"10.1093\/annonc\/mdi217_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.leu.2403295","article-title":"Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells","volume":"18","author":"Hahntow","year":"2004","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdi217_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.2004.04901.x","article-title":"Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E\/cdk2 as a potential therapeutic target","volume":"125","author":"Decker","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi217_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/path.1254","article-title":"Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression","volume":"199","author":"Khoury","year":"2003","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdi217_bb0095","doi-asserted-by":"crossref","first-page":"32089","DOI":"10.1074\/jbc.M005267200","article-title":"Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release","volume":"275","author":"Achenbach","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdi217_bb0100","first-page":"8523","article-title":"Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2","volume":"63","author":"Mohapatra","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/sj.onc.1207025","article-title":"Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP","volume":"23","author":"Kim","year":"2004","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdi217_bb0110","article-title":"CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1","volume":"45","author":"MacCallum","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0115","first-page":"93","article-title":"Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis","volume":"63","author":"Wittmann","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0120","first-page":"3527","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1","volume":"8","author":"Gojo","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0125","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1038\/sj.onc.1206863","article-title":"Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK\/JNK- and NF-kappaB-dependent process","volume":"22","author":"Dai","year":"2003","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdi217_bb0130","first-page":"73","article-title":"Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1","volume":"2","author":"Ma","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdi217_bb0135","first-page":"4634","article-title":"Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol","volume":"59","author":"Carlson","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-10-research0041","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol","volume":"2","author":"Lam","year":"2001","journal-title":"Genome Biol"},{"key":"10.1093\/annonc\/mdi217_bb0145","first-page":"785","article-title":"The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382","volume":"60","author":"Ljungman","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1093\/annonc\/mdi217_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) Inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0155","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bcp.2004.02.007","article-title":"Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons","volume":"67","author":"Monaco","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1093\/annonc\/mdi217_bb0160","first-page":"7410","article-title":"Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity","volume":"63","author":"Jiang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0165","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood.V99.12.4554","article-title":"Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes","volume":"99","author":"Korz","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi217_bb0170","first-page":"1822","article-title":"The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase\/Akt-dependent process","volume":"63","author":"Yu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi217_bb0175","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2004-02-0483","article-title":"Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences","volume":"104","author":"Liu","year":"2004","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/7\/1169\/398125\/mdi217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:55:37Z","timestamp":1582217737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419476825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0923753419476825"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi217","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}